Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lidocaine + sufentanil
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous, Topical, Epidural, Intrathecal
01
Overview
Lidocaine + sufentanil is a combination of two drugs used in anesthesia and pain management. Lidocaine is a local anesthetic that works by blocking sodium channels to prevent pain signals from being transmitted by nerves. Sufentanil is a potent opioid analgesic and a specific μ-opioid receptor agonist with fast onset of action, strong analgesic effect, and good hemodynamic stability. The combination is used in various medical procedures including upper gastrointestinal endoscopy and potentially for other types of anesthesia or analgesia.
- Other names
- sufentanil and lidocainesufentanil plus lidocaine
02
Targets
MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on lidocaine + sufentanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lidocaine + sufentanil.